OmniAb (OABI) Q1 2025 earnings summary

Executive summary

• Achieved robust deal flow in Q1 2025, including new partner signings, platform and asset-based deals, and the launch of the xploration Partner Access Program to enhance technology scalability and business opportunities.

• Maintained a diversified pipeline with 95 active partners and 378 active programs as of March 31, 2025, including 33 in clinical development or commercialization.

• Entered new platform license agreements and collaborations, including with Wyss Institute at Harvard, Takis Biotech, and Orion Corporation, with potential milestones exceeding $55 million and royalties.

• Post-quarter, completed an asset-based sale with Angelini Pharma for a small molecule program, with $3 million upfront and potential milestones over $170 million.

• Revenue is primarily from license fees, milestones, and service revenue, with long-term value expected from royalties on partner product sales.

Financial highlights

• Q1 2025 revenue was $4.2 million, up from $3.8 million in Q1 2024, driven by higher milestone and license revenue, partially offset by lower service and royalty revenue.

• Operating expenses declined to $23.0 million from $26.4 million year-over-year, mainly due to lower R&D and G&A costs.

• Net loss for Q1 2025 was $18.2 million ($0.17 per share), compared to $19.0 million ($0.19 per share) in Q1 2024.

• Cash, cash equivalents, and short-term investments totaled $43.6 million as of March 31, 2025.

• Net cash used in operating activities was $15.9 million for Q1 2025, down from $17.0 million in Q1 2024.

Outlook and guidance

• 2025 revenue guidance affirmed at $20–$25 million, excluding potential contributions from the xploration Partner Access Program.

• Operating expense guidance lowered to $85–$90 million (from $90–$95 million), with 40% being non-cash expenses.

• 2025 cash use expected to be lower than 2024, which was $38.9 million (excluding ATM issuance).

• Management expects existing cash and investments to support operations for at least the next 12 months.

• Full-year 2025 effective tax rate expected to be approximately 0%.